Global Osteoarthritis Therapeutics Market, By Drug Type (Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids, and Others), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Others), Route of Administration (Parenteral Route, Topical Route, and Oral Route), Sales Channel (Prescription Drugs and Over-the-Counter Drugs), End-use (Hospital Pharmacies, Retail Pharmacies, and Others) – Industry Trends and Forecast to 2031.
Osteoarthritis Therapeutics Market Analysis and Size
The osteoarthritis therapeutics market continues to advance with the latest methods and technologies, driving growth. Innovations in biologics, regenerative medicine, and personalized treatments are reshaping care paradigms. This evolution promises enhanced efficacy, reduced side effects, and improved patient outcomes. As research expands, the market is poised for substantial expansion, addressing unmet needs and offering new hope to millions affected by osteoarthritis.
The global osteoarthritis therapeutics market size was valued at USD 7.96 billion in 2023, is projected to reach USD 15.86 billion by 2031, with a CAGR of 9% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Type (Viscosupplementation Agents, Nonsteroidal Anti-inflammatory Drugs, Analgesics, Corticosteroids, and Others), Anatomy (Knee Osteoarthritis, Hip Osteoarthritis, Hand Osteoarthritis, and Others), Route of Administration (Parenteral Route, Topical Route, and Oral Route), Sales Channel (Prescription Drugs and Over-the-Counter Drugs), End-use (Hospital Pharmacies, Retail Pharmacies, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Samsung Bioepis (South Korea), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca PLC (U.K.), Zimmer Biomet (U.S.), and Stryker Corporation (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Osteoarthritis therapeutics aim to manage pain, reduce inflammation, and improve joint function. Treatments include nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief, physical therapy to strengthen muscles and improve flexibility, corticosteroid injections for inflammation, and lifestyle modifications such as weight management and gentle exercise. In severe cases, surgical options such as joint replacement may be considered to restore mobility and quality of life.
Osteoarthritis Therapeutics Market Dynamics
Drivers
- Increasing Aging Population
The increasing global aging population is significantly driving the demand for osteoarthritis therapeutics. With age being a primary risk factor, the prevalence of osteoarthritis is rising, necessitating more effective treatments. For instance, in the U.S. alone, over 32 million adults aged 45 and older are affected by osteoarthritis of the knee, highlighting the substantial market need for innovative therapies that can alleviate pain and improve mobility in aging individuals.
- Patient Preference for Pain Management
The preference of osteoarthritis patients for effective pain relief is a significant driver of the therapeutics market. This demand fuels the development and adoption of pharmaceuticals, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics, as well as alternative treatments such as physical therapy and acupuncture. For instance, the popularity of glucosamine supplements among patients reflects the ongoing search for solutions that alleviate pain and improve quality of life, thereby propelling market growth.
Opportunities
- Demand for Minimally Invasive Procedures
The demand for minimally invasive osteoarthritis therapeutic procedures in treatment is surging, fueling market growth. Patients increasingly opt for less invasive surgical interventions such as arthroscopy over traditional joint replacement surgeries, due to quicker recovery times and reduced risk of complications. Additionally, non-pharmacological therapies such as physical therapy and acupuncture are gaining popularity for their effectiveness in pain management and improving joint function. These trends are reshaping treatment approaches and expanding the osteoarthritis therapeutics market globally.
- Advancements in Medical Technology
Advancements in medical technology, such as high-resolution MRI and CT scans, enable more accurate diagnosis of osteoarthritis, guiding precise treatment plans. Moreover, the development of biologics and regenerative medicine therapies, such as platelet-rich plasma injections and stem cell therapies, offer promising alternatives to conventional treatments. These innovations not only improve patient outcomes by targeting disease mechanisms more effectively but also stimulate market growth through the introduction of novel and effective therapeutic options.
Restraints/Challenges
- High Cost of Treatment
The high cost of osteoarthritis treatments, including biologics and joint replacement surgeries, serves as a significant barrier by restricting access for a substantial portion of the patient population. This economic hurdle hinders market growth by preventing widespread adoption of these therapies, exacerbating disparities in healthcare access and affordability.
- Lack of Biomarkers for Disease Progression
The absence of reliable biomarkers for monitoring osteoarthritis progression hinders the development of targeted therapies and personalized treatment approaches. This limitation complicates clinical trials, delays regulatory approvals, and restricts the ability to tailor treatments to individual patient needs, thereby impeding market growth and innovation in osteoarthritis therapeutics.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In September 2022, Alkem Laboratories secured regulatory approval from the Drug Controller General of India (DCGI) for StemOne, an off-the-shelf cell therapy jointly developed with Stempeutics. This innovative product targets knee osteoarthritis, a prevalent degenerative joint disease in India, marking a significant milestone for Alkem in the realm of regenerative medicine
- In August 2022, Shionogi & Co., Ltd., and Grünenthal GmbH finalized a licensing agreement to bring injectable resiniferatoxin, a promising pipeline product of Grünenthal, to Japan. The therapy aims to alleviate pain in patients suffering from knee osteoarthritis, addressing a critical medical need in the Japanese market with its innovative pain management approach
Osteoarthritis Therapeutics Market Scope
The market is segmented on the basis of drug type, anatomy, route of administration, sales channel, and end-use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Type
- Viscosupplementation Agents
- Nonsteroidal Anti-inflammatory Drugs
- Naproxen
- Aspirin
- Diclofenac
- Ibuprofen
- Celecoxib
- Meloxicam
- Piroxicam
- Ketoprofen
- Other NSAIDs
- Analgesics
- Duloxetine
- Acetaminophen
- Corticosteroids
- Others
Anatomy
- Knee Osteoarthritis
- Hip Osteoarthritis
- Hand Osteoarthritis
- Others
Route of Administration
- Parenteral Route
- Hyaluronic Acid Injections
- Corticosteroid Injections
- Platelet-rich Plasma (PRP) Injections
- Placental Tissue Matrix (PTM) Injections
- Acetylsalicylic Acid (ASA) Injections
- Others
- Topical Route
- Oral Route
Sales Channel
- Prescription Drugs
- Over-the-Counter Drugs
End-use
- Hospital Pharmacies
- Retail Pharmacies
- Others
Osteoarthritis Therapeutics Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, drug type, anatomy, route of administration, sales channel, and end-use as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the osteoarthritis therapeutics market owing to its leadership in research and development, a high prevalence of obesity, and rising cases of osteoarthritis. These factors position the region at the forefront of advancements in treatment and management strategies.
Asia-Pacific is expected to account for the largest market share in the osteoarthritis therapeutics market, driven by developing healthcare facilities, effective cure for osteoarthritis therapeutic area, a high number of generic manufacturers, and increasing government initiatives and specialist communities focusing on joint health.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Osteoarthritis Therapeutics Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Pfizer Inc. (U.S.)
- Abbvie Inc. (U.S.)
- Novartis AG (Switzerland)
- Amgen Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Samsung Bioepis (South Korea)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- AstraZeneca PLC (U.K.)
- Zimmer Biomet (U.S.)
- Stryker Corporation (U.S.)
SKU-